Nodus Oncology launches with funding from Cumulus

6 September 2022

Nodus Oncology, a novel biotech company focused on developing first and best-in-class molecules inhibiting novel DNA damage response (DDR) targets, has launched with seed funding from Cumulus Oncology and announced a partnership with the Lead Discovery Center (LDC).

The Scottish company is being led by chief executive Ian Waddell, who also serves chief scientific officer at Cumulus. Dr Waddell has more than 30 years’ experience in leading successful R&D programs as well as extensive and in-depth oncology expertise, including in the DDR field.

He said: "I am excited to launch Nodus Oncology today and to be leading the company as its chief executive as we look to grow the company and its pipeline. Nodus is focused on developing the next wave of cancer therapeutics in the DDR space and I am looking forward to working with colleagues at LDC to pursue the development of differentiated programs against new targets in the DDR area."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK